Reduce Cytomel (Liothyronine) First
When a patient on combination levothyroxine and liothyronine therapy presents with a low TSH, you should reduce or discontinue the Cytomel (liothyronine) first. This is because liothyronine has a rapid onset and dissipation of action, allowing for quicker dose adjustments and faster normalization of TSH levels 1.
Rationale for Adjusting Liothyronine First
The FDA labeling for Cytomel explicitly notes that liothyronine has "rapid cutoff" with metabolic effects persisting only "a few days following discontinuance" 1. This pharmacokinetic profile makes it the ideal medication to adjust when TSH suppression occurs because:
- Faster response time: Changes in liothyronine dosing will affect TSH levels within days rather than weeks
- Easier titration: Liothyronine comes in smaller dose increments (5 mcg) compared to the typical levothyroxine adjustments needed
- Reversibility: If you overshoot the adjustment, the effects dissipate quickly
In contrast, levothyroxine has a much longer half-life, meaning dose adjustments take 4-8 weeks to reach steady state and fully manifest their effects on TSH 2.
Practical Adjustment Strategy
- Reduce liothyronine by 5 mcg daily (or reduce one of the twice-daily doses if the patient takes it split)
- Recheck TSH in 2-3 weeks (much sooner than the typical 4-8 weeks needed for levothyroxine adjustments)
- If TSH remains suppressed, consider further liothyronine reduction or discontinuation
- Only adjust levothyroxine if liothyronine has been discontinued entirely and TSH remains low after 4-6 weeks
Important Caveats
Avoid overtreatment: A suppressed TSH carries significant risks, particularly cardiovascular complications (atrial fibrillation) and skeletal effects (accelerated bone loss), especially in elderly and postmenopausal women 2. The wide swings in serum T3 levels following liothyronine administration increase the possibility of cardiovascular side effects 1.
Monitor for symptoms: While adjusting doses, assess for signs of hyperthyroidism (palpitations, tremor, anxiety, heat intolerance). The goal TSH for most non-pregnant adults on thyroid replacement is 0.5-2.0 mIU/L 3.
Consider discontinuing combination therapy entirely: Current guidelines do not support routine use of combination therapy over levothyroxine monotherapy 2, 4. If the patient was started on combination therapy for persistent symptoms, and TSH is now suppressed, this may be an appropriate time to transition back to levothyroxine monotherapy and reassess symptom control after achieving a normal TSH.